ClinicalTrials.gg
CompletedNCT03888755Updated Jun 3, 2021Results posted

A Study of Icatibant for Acute Attacks of Hereditary Angioedema in Japanese Participants

A Phase 3 interventional study of Icatibant in Hereditary Angioedema (HAE), sponsored by Shire. Completed at 8 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-03.

Sponsored by Shire (part of Takeda) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 years after the study started (first participant enrolled Mar 2015, registered Mar 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing icatibant in Angioedemas, Hereditary — none open to participants now, none under way, none of them phase 3. icatibant · Angioedemas, Hereditary.

Enrollment
8th of 10
8 · median 26
Started
2015
the only one that year
Phase 3
7 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
7 of 10
Shire

Among the 10 studies testing icatibant in Angioedemas, Hereditary, this one is the 8th largest by enrollment, is the only one that started in 2015, is one of 7 in phase 3, and was the 8th registered.

Angioedemas, Hereditary

171 studies on the registry are indexed under Angioedemas, Hereditary; 24 are open to participants now.

Browse Angioedemas, Hereditary studies →

Open to participants now

None of the 10 studies testing icatibant in Angioedemas, Hereditary is open now. The open studies under Angioedemas, Hereditary, anywhere →

About icatibant

icatibant: first FDA approval 2011 (FIRAZYR), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 13 Angioedemas, Hereditary studies recruiting now, 9 (69%) set no upper age limit and 4 (31%) stop at 75 or younger; 7 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing icatibant in Angioedemas, Hereditary as a file.
02

Study summary

The objective of this study is to evaluate the efficacy, pharmacokinetics (PK), and safety of icatibant for the treatment of acute attacks in Japanese participants with type I or type II hereditary angioedema (HAE).

03

Conditions studied

  • Hereditary Angioedema (HAE)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The participant is in Japan and is Japanese; defined as born in Japan and having Japanese parents and Japanese maternal and paternal grandparents.
  2. The participant is male or female and greater than or equal to (>=) 18 years of age at the time of .
  3. The participant has a confirmed diagnosis of hereditary angioedema (HAE) type I or II. Diagnosis may be based on historical data using the following criteria:

    1. Family history of angioedema
    2. Characteristic attack manifestations, recurrent attacks
    3. C1 esterase inhibitor (C1-INH) deficiency
    4. In the absence of a family history of angioedema, exclusion of other forms of angioedema (example: acquired angioedema)
  4. If the participant does not have a confirmed diagnosis of HAE type I or II based on historical data, including C1-INH deficiency, the participant's diagnosis must be determined prior to treatment by C1-NH test results which demonstrate a quantitative and/or functional C1-INH deficiency.

    1. HAE type I: Low amount of C1-INH protein and low level of C1-INH activity; HAE type; II: Normal or increased amount of C1-INH protein and low level of C1-INH activity
    2. In the absence of a family history of angioedema, exclusion of other forms of angioedema based on a normal level of C1q.
  5. The current HAE attack must be in the cutaneous, abdominal, and/or laryngeal (inclusive of laryngeal and pharyngeal) areas.
  6. The attack must be moderate to severe for non-laryngeal and mild to moderate for laryngeal as determined by investigator global assessment at pretreatment (baseline).
  7. The participant commences treatment within 6 hours of the attack becoming at least mild (laryngeal) or moderate (non-laryngeal) in severity, but not more than 12 hours (h) after the onset of the attack. Note: for participant who present to the hospital/clinic with symptoms which have already progressed to at least moderate (non-laryngeal) or mild (laryngeal) severity, their duration can be estimated by the investigator through questioning of the participant.
  8. The participant (or the participant's parent/legal guardian, if applicable) has provided written informed consent which has been approved by the Institutional Review Board/Independent Ethics Committee (IRB/IEC).

    1. If the participant is an adult, be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed. OR
    2. If the participant is a minor (that is [i.e.] \< 20 years of age), have a parent/legal guardian who is informed of the nature of the study provide written informed consent (i.e., permission) for the minor to participate in the study before any study-specific procedures are performed; Assent will be obtained from minor participants.
  9. Females of must have a negative urine pregnancy test and must use medically acceptable methods to prevent pregnancy during their active participation in the study, (time from icatibant treatment of the acute attack to the follow-up visit at Day 7 [+3 days]), with the exception of those females who have had a total hysterectomy or bilateral oophorectomy, or who are 2 years post menopausal.

Exclusion criteria

Exclusion Criteria:

  1. The participant will require an intervention to support the airway (example: intubation, tracheotomy, cricothyrotomy) due to the current attack of angioedema.
  2. The participant presents with an HAE attack with laryngeal/upper respiratory tract symptoms which are considered severe in the investigator's clinical judgment and in conjunction with the investigator global assessment and which may necessitate urgent care and/or impede the conduct of study efficacy assessments.
  3. The participant has a diagnosis of angioedema other than HAE (non-hereditary angioedema, example: acquired angioedema).
  4. The participant has received previous treatment with icatibant.
  5. The participant is enrolled in another clinical study that involves investigation or use of any product (drug or device) within 30 days prior to study enrollment or at any time during the study.
  6. The participant has received treatment with any pain medication since the onset of the current angioedema attack.
  7. The participant has received replacement therapy (C1-INH products, fresh frozen plasma [FFP]) \< 5 days (120 hours) from the onset of the current angioedema attack.
  8. The participant is receiving treatment with angiotensin converting enzyme (ACE) inhibitors.
  9. The participant has evidence of coronary artery disease based on medical history at the screening examination or at pretreatment; example: unstable angina pectoris or severe coronary heart disease and congestive heart failure, that in the investigator's judgment would be a for participation in the trial ( [NYHA] class 3 and 4).
  10. The participant has a serious pre-existing condition or condition that, in the opinion of the investigator, would be a contraindication for participation in the trial.
  11. The participant is pregnant or breastfeeding.
  12. The participant is unable to understand the nature, scope, and possible consequences of the protocol, or is unlikely to comply with the protocol assessments, unable to return for follow up visits, or unlikely to complete the study for any reason.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Icatibant

    Participants with 1 acute non-laryngeal or laryngeal attack will receive a single icatibant 30 milligram (mg) subcutaneous (SC) injection in the abdominal area. A maximum of 3 SC injections (or 90 mg) of icatibant that are at least 6 hours apart can be given for treatment of an attack if, within 48 hours of the initial treatment, there is insufficient relief or worsening of symptoms.

    Drug: Icatibant

Interventions

  • Participants will receive icatibant 30 mg SC injection in the abdominal area.

06

What researchers measure

Primary outcomes

  1. Time to Onset of Symptom Relief (TOSR)

    The TOSR was defined as a 50 percent (%) reduction from the pre-treatment score in the 3-symptom composite VAS score for non-laryngeal attacks and 5-symptom composite VAS score for laryngeal attacks. A VAS utilizes a scale consisting of a 100 millimeter (mm) horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The participant should draw a vertical line at the point along the scale that represents the current status of the measured symptom. Composite VAS scores were calculated as the average of VAS measurements for skin swelling, skin pain, and abdominal pain (3-symptom composite) for non-laryngeal attacks and for skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change (5-symptom composite) for laryngeal attacks.

    Time frame: Baseline up to 120 hours post-treatment

Secondary outcomes

  1. Time to Onset of Primary Symptom Relief (TOSR-P)

    Primary symptom relief was based on the participant-assessed VAS score for a single primary symptom (determined by edema location) and corresponds to a reduction by 31 mm at a pretreatment VAS of 100 mm and by 21 mm at a pretreatment VAS of 30 mm. If the primary symptom pretreatment VAS less than (\<) 30 mm, then primary symptom relief was defined as 68% reduction from pretreatment. A VAS utilizes a scale consisting of a 100 millimeter (mm) horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The TOSR-P was calculated from the time of icatibant administration to the onset of primary symptom relief.

    Time frame: Baseline up to 120 hours post-treatment

  2. Change From Baseline in the Composite Visual Analog Scale (VAS) Score

    A VAS utilizes a scale consisting of a 100 mm horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The participant should draw a vertical line at the point along the scale that represents the current status of the measured symptom. Composite VAS scores was calculated as the average of VAS measurements for skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change (5-symptom composite) for laryngeal attacks and as the average of VAS measurements for skin swelling, skin pain and abdominal pain (3-symptom composite) for non-laryngeal attacks. Change from baseline in the composite VAS score was reported.

    Time frame: Baseline, 2, 4 and 8 hours post-treatment

  3. Composite Symptom Score (SS) Assessed by Investigator

    The investigator-assessed composite symptom score was calculated as an average of abdominal tenderness, nausea, vomiting, diarrhea, skin pain, erythema, skin irritation, and skin swelling (8 symptoms) for non-laryngeal attacks and the average of abdominal tenderness, nausea, vomiting, diarrhea, skin pain, erythema, skin irritation, skin swelling, dysphagia, voice change, breathing difficulties, stridor, and asphyxia (13 symptoms) for laryngeal attacks using the following 5-point scale 0 = none (absence of symptoms); 1 = mild (no to mild interference with daily activities); 2 = moderate (moderate interference with daily activities); 3 = severe (severe interference with daily activities); 4 = very severe (very severe interference with daily activities). Here the composite SS assessed by investigator was reported.

    Time frame: 8 hours post dose

  4. Composite Symptom Score (SS) Assessed by Participant

    The participant-assessed composite symptom score was calculated as an average of abdominal pain, nausea, vomiting, diarrhea, skin pain, erythema, skin irritation, and skin swelling (8 symptoms) for non-laryngeal attacks and the average of abdominal pain, nausea, vomiting, diarrhea, skin pain, erythema,skin irritation, skin swelling, dysphagia and voice change (10 symptoms) for laryngeal attacks using the following 5-point scale 0 = none (absence of symptoms); 1 = mild (no to mild interference with daily activities); 2 = moderate (moderate interference with daily activities); 3 = severe (severe interference with daily activities); 4 = very severe (very severe interference with daily activities). Here the composite SS assessed by participant was reported.

    Time frame: 8 hours post dose

  5. Investigator Global Assessment

    The investigator was made a global assessment (that is \[i.e.\] consideration of all abdominal symptoms combined, all cutaneous symptoms combined and/or all laryngeal symptoms combined) using the following 5-point scale, where the symptoms were scored from 0 for "absence of symptoms" to 4 for "very severe": 0 = none (absence of symptoms); 1 = mild (no to mild interference with daily activities); 2 = moderate (moderate interference with daily activities); 3 = severe (severe interference with daily activities); 4 = very severe (very severe interference with daily activities).

    Time frame: 2, 4 and 8 hours post dose

  6. Time to Initial Symptom Improvement by Investigator

    Time to initial symptom improvement was evaluated by the investigator; each were asked to record the time at which they perceived initial improvement of symptoms. Time to initial symptom improvement was calculated from the time of icatibant administration to the time reported by the investigator of initial improvement of symptoms.

    Time frame: Baseline up to 120 hours post-treatment

  7. Time to Initial Symptom Improvement by Participants

    Time to initial symptom improvement was evaluated by the participants; each were asked to record the time at which they perceived initial improvement of symptoms. Time to initial symptom improvement was calculated from the time of icatibant administration to the time reported by the participant of initial improvement of symptoms.

    Time frame: Baseline up to 120 hours post-treatment

  8. Time to Almost Complete Symptom Relief As Assessed by Visual Analog Scale (VAS) Score

    Time to almost complete symptom relief was calculated from the time of icatibant administration to almost complete symptom relief. Almost complete symptom relief was determined retrospectively as the earliest of three consecutive non-missing measurements for which all VAS scores \< 10 mm. A VAS utilizes a scale consisting of a 100 millimeter (mm) horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The participant should draw a vertical line at the point along the scale that represents the current status of the measured symptom.

    Time frame: Baseline up to 120 hours post-treatment

  9. Maximum Observed Plasma Concentration (Cmax) of Icatibant After a Single Subcutaneous (SC) Administration of Icatibant

    The Cmax was estimated by a population PK modeling approach. The Cmax of icatibant was reported.

    Time frame: Baseline, 0.75, 2 hours post-treatment

  10. Area Under the Concentration-time Curve From 0 to 2 Hours (AUC0-2) After a Single Subcutaneous (SC) Administration of Icatibant

    The AUC0-2 was estimated by a population PK modeling approach. The AUC0-2 of Icatibant was reported.

    Time frame: Baseline, 0.75, 2 hours post-treatment

  11. Area Under the Concentration-time Curve From 0 to 4 Hours (AUC0-4) After a Single Subcutaneous (SC) Administration of Icatibant

    The AUC0-4 was estimated by a population PK modeling approach. The AUC0-4 of Icatibant was reported.

    Time frame: Baseline, 0.75, 2 hours post-treatment

  12. Area Under the Concentration-time Curve From 0 to 6 Hours (AUC0-6) After a Single Subcutaneous (SC) Administration of Icatibant

    The AUC0-6 was estimated by a population PK modeling approach. The AUC0-6 of Icatibant was reported.

    Time frame: Baseline, 0.75, 2 hours post-treatment

  13. Number of Participants With Treatment-Emergent Adverse Events (TEAEs)

    An AE was any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurred in any phase of a clinical study, whether or not considered investigational product related. The TEAEs were defined as all AEs occurred on or after the time of study drug administration.

    Time frame: From start of study drug administration to follow-up (up to 10 days)

  14. Number of Participants With Injection Site Reactions Reported as Adverse Event (AE)

    Number of participants with injection site reactions (erythema, swelling, cutaneous pain, burning sensation, itching/pruritus, and warm sensation) were reported.

    Time frame: From start of study drug administration to follow-up (up to 10 days)

  15. Number of Participants With Clinically Significant Changes in Clinical Laboratory Tests Reported as Adverse Event (AE)

    Clinical laboratory tests included serum chemistry, hematology, urinalysis and coagulation were assessed. Number of participants with clinically significant changes in clinical laboratory tests were reported.

    Time frame: From start of study drug administration to follow-up (up to 10 days)

  16. Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Event (AE)

    Vital signs included pulse rate, blood pressure, respiration rate, and temperature. The number of participants with clinically significant changes in vital signs were reported.

    Time frame: From start of study drug administration to follow-up (up to 10 days)

  17. Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Adverse Event (AE)

    A standard 12-lead ECG was performed. The number of participants who reported clinically significant changes in ECGs were reported.

    Time frame: From start of study drug administration to follow-up (up to 10 days)

07

Results

Posted Aug 8, 2019

Participant flow

The study was conducted at 8 sites in Japan between 18 March 2015 (first participant first visit) and 12 February 2016 (last participant last visit).

Participant flow — Overall Study
MilestoneIcatibant
Started8
Completed8
Not completed0

Outcome measures

PrimaryTime to Onset of Symptom Relief (TOSR)

The TOSR was defined as a 50 percent (%) reduction from the pre-treatment score in the 3-symptom composite VAS score for non-laryngeal attacks and 5-symptom composite VAS score for laryngeal attacks. A VAS utilizes a scale consisting of a 100 millimeter (mm) horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The participant should draw a vertical line at the point along the scale that represents the current status of the measured symptom. Composite VAS scores were calculated as the average of VAS measurements for skin swelling, skin pain, and abdominal pain (3-symptom composite) for non-laryngeal attacks and for skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change (5-symptom composite) for laryngeal attacks.

Time frame:
Baseline up to 120 hours post-treatment
Reported as:
Median · Hours
Time to Onset of Symptom Relief (TOSR)
HoursIcatibant
Time to Onset of Symptom Relief (TOSR)1.75 (1.00 to 2.50)
SecondaryTime to Onset of Primary Symptom Relief (TOSR-P)

Primary symptom relief was based on the participant-assessed VAS score for a single primary symptom (determined by edema location) and corresponds to a reduction by 31 mm at a pretreatment VAS of 100 mm and by 21 mm at a pretreatment VAS of 30 mm. If the primary symptom pretreatment VAS less than (\<) 30 mm, then primary symptom relief was defined as 68% reduction from pretreatment. A VAS utilizes a scale consisting of a 100 millimeter (mm) horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The TOSR-P was calculated from the time of icatibant administration to the onset of primary symptom relief.

Time frame:
Baseline up to 120 hours post-treatment
Reported as:
Median · Hours
Time to Onset of Primary Symptom Relief (TOSR-P)
HoursIcatibant
Time to Onset of Primary Symptom Relief (TOSR-P)1.07 (1.00 to 2.00)
SecondaryChange From Baseline in the Composite Visual Analog Scale (VAS) Score

A VAS utilizes a scale consisting of a 100 mm horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The participant should draw a vertical line at the point along the scale that represents the current status of the measured symptom. Composite VAS scores was calculated as the average of VAS measurements for skin swelling, skin pain, abdominal pain, difficulty swallowing, and voice change (5-symptom composite) for laryngeal attacks and as the average of VAS measurements for skin swelling, skin pain and abdominal pain (3-symptom composite) for non-laryngeal attacks. Change from baseline in the composite VAS score was reported.

Time frame:
Baseline, 2, 4 and 8 hours post-treatment
Reported as:
Mean · Score on a scale
Change From Baseline in the Composite Visual Analog Scale (VAS) Score
Score on a scaleIcatibant
Baseline30.78 ± 13.465
2 hours-19.26 ± 13.310
4 hours-24.57 ± 13.367
8 hours-29.40 ± 12.998
SecondaryComposite Symptom Score (SS) Assessed by Investigator

The investigator-assessed composite symptom score was calculated as an average of abdominal tenderness, nausea, vomiting, diarrhea, skin pain, erythema, skin irritation, and skin swelling (8 symptoms) for non-laryngeal attacks and the average of abdominal tenderness, nausea, vomiting, diarrhea, skin pain, erythema, skin irritation, skin swelling, dysphagia, voice change, breathing difficulties, stridor, and asphyxia (13 symptoms) for laryngeal attacks using the following 5-point scale 0 = none (absence of symptoms); 1 = mild (no to mild interference with daily activities); 2 = moderate (moderate interference with daily activities); 3 = severe (severe interference with daily activities); 4 = very severe (very severe interference with daily activities). Here the composite SS assessed by investigator was reported.

Time frame:
8 hours post dose
Reported as:
Mean · Score on a scale
Composite Symptom Score (SS) Assessed by Investigator
Score on a scaleIcatibant
Composite Symptom Score (SS) Assessed by Investigator0.12 ± 0.18
SecondaryComposite Symptom Score (SS) Assessed by Participant

The participant-assessed composite symptom score was calculated as an average of abdominal pain, nausea, vomiting, diarrhea, skin pain, erythema, skin irritation, and skin swelling (8 symptoms) for non-laryngeal attacks and the average of abdominal pain, nausea, vomiting, diarrhea, skin pain, erythema,skin irritation, skin swelling, dysphagia and voice change (10 symptoms) for laryngeal attacks using the following 5-point scale 0 = none (absence of symptoms); 1 = mild (no to mild interference with daily activities); 2 = moderate (moderate interference with daily activities); 3 = severe (severe interference with daily activities); 4 = very severe (very severe interference with daily activities). Here the composite SS assessed by participant was reported.

Time frame:
8 hours post dose
Reported as:
Mean · Score on a scale
Composite Symptom Score (SS) Assessed by Participant
Score on a scaleIcatibant
Composite Symptom Score (SS) Assessed by Participant0.14 ± 0.16
SecondaryInvestigator Global Assessment

The investigator was made a global assessment (that is \[i.e.\] consideration of all abdominal symptoms combined, all cutaneous symptoms combined and/or all laryngeal symptoms combined) using the following 5-point scale, where the symptoms were scored from 0 for "absence of symptoms" to 4 for "very severe": 0 = none (absence of symptoms); 1 = mild (no to mild interference with daily activities); 2 = moderate (moderate interference with daily activities); 3 = severe (severe interference with daily activities); 4 = very severe (very severe interference with daily activities).

Time frame:
2, 4 and 8 hours post dose
Reported as:
Mean · Score on a scale
Investigator Global Assessment
Score on a scaleIcatibant
Cutaneous Symptoms: 2 hours (h) post dose0.9 ± 0.99
Cutaneous Symptoms: 4 h post dose0.6 ± 0.52
Cutaneous Symptoms: 8 h post dose0.5 ± 0.53
Abdominal Symptoms: 2 h post dose0.1 ± 0.35
Abdominal Symptoms: 4 h post dose0.0 ± 0.00
Abdominal Symptoms: 8 h post dose0.0 ± 0.00
Laryngeal Symptoms: 2 h post dose0.0 ± 0.00
Laryngeal Symptoms: 4 h post dose0.0 ± 0.00
Laryngeal Symptoms: 8 h post dose0.0 ± 0.00
SecondaryTime to Initial Symptom Improvement by Investigator

Time to initial symptom improvement was evaluated by the investigator; each were asked to record the time at which they perceived initial improvement of symptoms. Time to initial symptom improvement was calculated from the time of icatibant administration to the time reported by the investigator of initial improvement of symptoms.

Time frame:
Baseline up to 120 hours post-treatment
Reported as:
Median · H
Time to Initial Symptom Improvement by Investigator
HIcatibant
Time to Initial Symptom Improvement by Investigator0.98 (0.30 to 2.00)
SecondaryTime to Initial Symptom Improvement by Participants

Time to initial symptom improvement was evaluated by the participants; each were asked to record the time at which they perceived initial improvement of symptoms. Time to initial symptom improvement was calculated from the time of icatibant administration to the time reported by the participant of initial improvement of symptoms.

Time frame:
Baseline up to 120 hours post-treatment
Reported as:
Median · h
Time to Initial Symptom Improvement by Participants
hIcatibant
Time to Initial Symptom Improvement by Participants1.04 (0.30 to 2.05)
SecondaryTime to Almost Complete Symptom Relief As Assessed by Visual Analog Scale (VAS) Score

Time to almost complete symptom relief was calculated from the time of icatibant administration to almost complete symptom relief. Almost complete symptom relief was determined retrospectively as the earliest of three consecutive non-missing measurements for which all VAS scores \< 10 mm. A VAS utilizes a scale consisting of a 100 millimeter (mm) horizontal line with extreme values at the beginning (0 mm = no symptom) and end (100 mm = worst possible symptom) of the line. The participant should draw a vertical line at the point along the scale that represents the current status of the measured symptom.

Time frame:
Baseline up to 120 hours post-treatment
Reported as:
Median · H
Time to Almost Complete Symptom Relief As Assessed by Visual Analog Scale (VAS) Score
HIcatibant
Time to Almost Complete Symptom Relief As Assessed by Visual Analog Scale (VAS) Score5.98 (2.27 to 8.00)
SecondaryMaximum Observed Plasma Concentration (Cmax) of Icatibant After a Single Subcutaneous (SC) Administration of Icatibant

The Cmax was estimated by a population PK modeling approach. The Cmax of icatibant was reported.

Time frame:
Baseline, 0.75, 2 hours post-treatment
Reported as:
Mean · Nano grams per milliliter (ng/mL)
Maximum Observed Plasma Concentration (Cmax) of Icatibant After a Single Subcutaneous (SC) Administration of Icatibant
Nano grams per milliliter (ng/mL)Icatibant
Maximum Observed Plasma Concentration (Cmax) of Icatibant After a Single Subcutaneous (SC) Administration of Icatibant405 ± 194
SecondaryArea Under the Concentration-time Curve From 0 to 2 Hours (AUC0-2) After a Single Subcutaneous (SC) Administration of Icatibant

The AUC0-2 was estimated by a population PK modeling approach. The AUC0-2 of Icatibant was reported.

Time frame:
Baseline, 0.75, 2 hours post-treatment
Reported as:
Mean · Nanograms*hour per milliliter (ng•h/mL)
Area Under the Concentration-time Curve From 0 to 2 Hours (AUC0-2) After a Single Subcutaneous (SC) Administration of Icatibant
Nanograms*hour per milliliter (ng•h/mL)Icatibant
Area Under the Concentration-time Curve From 0 to 2 Hours (AUC0-2) After a Single Subcutaneous (SC) Administration of Icatibant611 ± 338
SecondaryArea Under the Concentration-time Curve From 0 to 4 Hours (AUC0-4) After a Single Subcutaneous (SC) Administration of Icatibant

The AUC0-4 was estimated by a population PK modeling approach. The AUC0-4 of Icatibant was reported.

Time frame:
Baseline, 0.75, 2 hours post-treatment
Reported as:
Mean · ng•h/mL
Area Under the Concentration-time Curve From 0 to 4 Hours (AUC0-4) After a Single Subcutaneous (SC) Administration of Icatibant
ng•h/mLIcatibant
Area Under the Concentration-time Curve From 0 to 4 Hours (AUC0-4) After a Single Subcutaneous (SC) Administration of Icatibant1198 ± 495
SecondaryArea Under the Concentration-time Curve From 0 to 6 Hours (AUC0-6) After a Single Subcutaneous (SC) Administration of Icatibant

The AUC0-6 was estimated by a population PK modeling approach. The AUC0-6 of Icatibant was reported.

Time frame:
Baseline, 0.75, 2 hours post-treatment
Reported as:
Mean · ng•h/mL
Area Under the Concentration-time Curve From 0 to 6 Hours (AUC0-6) After a Single Subcutaneous (SC) Administration of Icatibant
ng•h/mLIcatibant
Area Under the Concentration-time Curve From 0 to 6 Hours (AUC0-6) After a Single Subcutaneous (SC) Administration of Icatibant1506 ± 509
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs)

An AE was any noxious, pathologic, or unintended change in anatomical, physiologic, or metabolic function as indicated by physical signs, symptoms, or laboratory changes occurred in any phase of a clinical study, whether or not considered investigational product related. The TEAEs were defined as all AEs occurred on or after the time of study drug administration.

Time frame:
From start of study drug administration to follow-up (up to 10 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)
ParticipantsIcatibant
Number of Participants With Treatment-Emergent Adverse Events (TEAEs)3
SecondaryNumber of Participants With Injection Site Reactions Reported as Adverse Event (AE)

Number of participants with injection site reactions (erythema, swelling, cutaneous pain, burning sensation, itching/pruritus, and warm sensation) were reported.

Time frame:
From start of study drug administration to follow-up (up to 10 days)
Reported as:
Count of participants · Participants
Number of Participants With Injection Site Reactions Reported as Adverse Event (AE)
ParticipantsIcatibant
Any Reaction7
Any Severe Reaction1
SecondaryNumber of Participants With Clinically Significant Changes in Clinical Laboratory Tests Reported as Adverse Event (AE)

Clinical laboratory tests included serum chemistry, hematology, urinalysis and coagulation were assessed. Number of participants with clinically significant changes in clinical laboratory tests were reported.

Time frame:
From start of study drug administration to follow-up (up to 10 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Clinical Laboratory Tests Reported as Adverse Event (AE)
ParticipantsIcatibant
Number of Participants With Clinically Significant Changes in Clinical Laboratory Tests Reported as Adverse Event (AE)0
SecondaryNumber of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Event (AE)

Vital signs included pulse rate, blood pressure, respiration rate, and temperature. The number of participants with clinically significant changes in vital signs were reported.

Time frame:
From start of study drug administration to follow-up (up to 10 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Event (AE)
ParticipantsIcatibant
Number of Participants With Clinically Significant Changes in Vital Signs Reported as Adverse Event (AE)0
SecondaryNumber of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Adverse Event (AE)

A standard 12-lead ECG was performed. The number of participants who reported clinically significant changes in ECGs were reported.

Time frame:
From start of study drug administration to follow-up (up to 10 days)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Adverse Event (AE)
ParticipantsIcatibant
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG) Reported as Adverse Event (AE)0

Adverse events

Collected over From start of study drug administration to 10 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Icatibant0/8 (0%)0/8 (0%)3/8 (37.5%)
Most frequent other events
Most frequent other events
EventIcatibant
HEREDITARY ANGIOEDEMACongenital, familial and genetic disorders2/8
HEADACHENervous system disorders1/8

Baseline characteristics

The treated population included all participants treated with icatibant.

Age, Continuous
Age, Continuous(Years)Icatibant
Mean45.5 ± 16.94
Sex: Female, Male
Sex: Female, Male(Participants)Icatibant
Female5
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Icatibant
American Indian or Alaska Native0
Asian8
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
08

Study locations

8 sites
  • Fukushima Medical University Hospital
    Fukushima, Japan
  • Hiroshima University Hospital
    Hiroshima, Japan
  • Kobe University Hospital
    Kobe, Japan
  • Saiseikai Kumamoto Hospital
    Kumamoto, Japan
  • Niigata City General Hospital
    Niigata, Japan
  • Nihon University Itabashi Hospital
    Tokyo, Japan
  • Tomakomai City Hospital
    Tomakomai, Japan
  • Yokohama City University Hospital
    Yokohama, Japan
09

References and documents

Individual participant data

Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

Data sharing details ↗ · vivli.org

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2015 to primary completion in Feb 2016, 10 months.

Results were first posted in Aug 2019, 3 years 5 months after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Angioedemas, Hereditary, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 33. This study's 10 months is below that.

Counting every sponsor, half of 46 studies reached it within 22 months; a quarter within 16 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2019
First posted
Mar 25, 2019
StartActual
Mar 18, 2015
Primary completionActual
Feb 12, 2016
CompletionActual
Feb 12, 2016
Results first posted
Aug 8, 2019
Last update
Jun 3, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03888755
Lead sponsor
Shire
Responsible party
Sponsor
First posted
Mar 25, 2019
Start date
Mar 18, 2015
Primary completion
Feb 12, 2016
Completion
Feb 12, 2016
Results posted
Aug 8, 2019
Last update
Jun 3, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Icatibant

Start the discussion